- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Tuesday, 10 September 2024
-
Current Status:
Answered by Neil Gray on 19 September 2024
To ask the Scottish Government what its response is to reports that NHS Western Isles has designated the refurbishment of Medical Ward 2 at the Western Isles Hospital in Stornoway as high priority, but that this work is reportedly unaffordable in the current financial year.
Answer
As a result of significant increases in construction costs due to inflation, and a lower than expected capital grant from the UK Government, a capital review is currently underway.
Alongside this, we are working with all health boards to develop a whole-system infrastructure plan which reflects on the needs for the whole of Scotland and will support continued safe operation of existing facilities and well as determination of longer-term investment priorities.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe ocrelizumab (Ocrevus) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
Jenni Minto: I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Siobhian Brown on 18 September 2024
To ask the Scottish Government whether it carried out an Island Communities Impact Assessment in advance of the reported end of grant funding agreements for advice services in the Western Isles on 31 March 2024, and, if this is not the case, for what reason.
Answer
An Island Communities Impact Assessment has been carried out and will be published on the Scottish Government’s website The Scottish Government - gov.scot (www.gov.scot) by the end of September 2024. The current grant funding provision for the Western Isles Advice Project which is part of the Scottish Legal Aid Board’s Early Resolution and Advice Programme, will continue under the existing criteria for funding until 30 September 2024.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe fingolimod (Gilenya) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe diroximel fumarate (Vumerity) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe Rebif (beta interferon-1a) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe cladribine (Mavenclad) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe ozanimod (Zeposia) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe glatiramer acetate (Copaxone) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
-
Date lodged: Friday, 06 September 2024
-
Current Status:
Answered by Jenni Minto on 18 September 2024
To ask the Scottish Government which NHS boards prescribe siponimod (Mayzent) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.
Answer
I refer the member to the answer to question S6W-29676 on 18 September 2024. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.